Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 4/20 | 0.51 |
| ▸ | USP2 | O75604 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KCNJ1 | P48048 | 9/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16432659 | 0.93 | ALDH1A1 (0.50) | RETUSP2ALDH1A1HSD17B10CYP2D6 | |
| SCHEMBL21522397 | 0.92 | RET (0.52) | RETUSP2ALDH1A1HSD17B10CYP2D6 | |
| SCHEMBL30101497 | 0.92 | RET (0.52) | RETUSP2ALDH1A1HSD17B10CYP2D6 | |
| SCHEMBL16438702 | 0.92 | USP2 (0.57) | RETUSP2ALDH1A1HSD17B10CYP2D6 | |
| SCHEMBL16430513 | 0.90 | ALDH1A1 (0.56) | RETUSP2ALDH1A1HSD17B10CYP2D6 | |
| SCHEMBL21521519 | 0.89 | RET (0.49) | RETALDH1A1HSD17B10CYP3A4HPGD | |
| SCHEMBL21521793 | 0.86 | RET (0.51) | RETUSP2ALDH1A1HSD17B10CYP2D6 | |
| SCHEMBL21521374 | 0.83 | HRH3 (0.48) | RETUSP2ALDH1A1HSD17B10CYP2D6 | |
| SCHEMBL16433202 | 0.83 | ALDH1A1 (0.49) | RETUSP2ALDH1A1HSD17B10CYP2D6 | |
| SCHEMBL16432851 | 0.82 | KCNJ1 (0.48) | KCNJ1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| EP-4234551-A2 | PYRIDAZINONES AS PARP7 INHIBITORS | Ribon Therapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2023-06-22 | — | — | US | disclosed |
| EP-3788040-B1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS INC (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11566020-B1 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11014913-B2 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| EP-3788040-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | Ribon Therapeutics Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20210024502-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2021-01-28 | — | — | US | disclosed |
| US-10870641-B2 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20200123134-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2020-04-23 | — | — | US | disclosed |
| EP-3027625-B1 | SPIRO-FUSED DERIVATIVES OF PIPERIDINE USEFUL FOR THE TREATMENT OF INTER ALIA HYPERTENSION AND ACUTE OR CHRONIC HEART FAILURE | MERCK SHARP & DOHME (US) | 2018-05-30 | — | — | EP | disclosed |
| US-9751881-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751881-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751881-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160207922-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME CORP. (US) | 2016-07-21 | — | — | US | disclosed |
| US-20160207922-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME CORP. (US) | 2016-07-21 | — | — | US | disclosed |
| US-20160207922-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME CORP. (US) | 2016-07-21 | — | — | US | disclosed |
| EP-3027625-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015017305-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP (US) | 2015-02-05 | — | — | WO | disclosed |
| WO-2015017305-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP (US) | 2015-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024502-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | RET 2740/4885USP2 3352/4885ALDH1A1 1033/4885 |
| US-20160207922-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | KCNJ11, KCNJ1, KCNJ2 | RET 681/4885USP2 4805/4885ALDH1A1 1722/4885 |
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | RET 2740/4885USP2 3352/4885ALDH1A1 1033/4885 |
| US-11014913-B2 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | RET 2740/4885USP2 3352/4885ALDH1A1 1033/4885 |
| US-11566020-B1 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | RET 2740/4885USP2 3352/4885ALDH1A1 1033/4885 |
| US-10870641-B2 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | RET 2740/4885USP2 3352/4885ALDH1A1 1033/4885 |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | RET 2740/4885USP2 3352/4885ALDH1A1 1033/4885 |
| US-20200123134-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | RET 2740/4885USP2 3352/4885ALDH1A1 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.